EVR:LSEEvraz PLC Analysis
Data as of 2026-03-12 - not real-time
$276.44
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Evercore Inc. (EVR) is trading at roughly $276, well below its DCF‑derived fair value of $851, implying a potential upside of over 40% and an undervalued positioning. The stock’s RSI of 30 suggests it is oversold, while the 20‑day SMA (≈$309) sits above the current price, pointing to short‑term support near $271. Fundamentally, revenue grew 32% YoY, gross margins remain exceptionally high at 93%, and operating margins are solid at 24.6%, delivering a ROE of 30%. The forward PE of 12 versus the industry average of 16 underscores a growth tilt, and a modest dividend yield of 1.17% with a low 23.6% payout ratio signals sustainability. Recent analyst sentiment has turned positive, highlighted by an upgrade to Zacks Rank 2 Buy, reinforcing the bullish narrative. However, the stock carries a high beta of 1.8 and 30‑day volatility near 51%, indicating heightened market sensitivity and a max drawdown of ~28% in recent history. Liquidity is stable but modest, with daily volumes around 300k shares. Overall, EVR offers a compelling blend of growth, value, and dividend appeal, but investors should weigh the elevated systematic risk.
Given these dynamics, the near‑term price action may test the $271 support before any upside move, while medium‑ to long‑term horizons remain attractive provided the firm sustains its margin profile and growth trajectory.
Given these dynamics, the near‑term price action may test the $271 support before any upside move, while medium‑ to long‑term horizons remain attractive provided the firm sustains its margin profile and growth trajectory.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- RSI at oversold levels (~30)
- Price near technical support (~$271)
- Sustainable dividend with low payout
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth (32% YoY)
- Significant valuation upside (>40%)
- Positive analyst upgrade to Zacks Rank 2 Buy
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- High ROE (30%) and robust margins
- Undervalued relative to DCF fair value
- Low dividend payout supporting cash generation
Key Metrics & Analysis
Financial Health
Revenue Growth32.20%
Profit Margin15.35%
P/E Ratio19.7
ROE30.07%
ROA13.44%
Debt/Equity49.79
P/B Ratio5.2
Op. Cash Flow$1.3B
Industry P/E16.4
Technical Analysis
TrendNeutral
RSI30.3
Support$270.91
Resistance$352.11
MA 20$309.29
MA 50$340.61
MA 200$314.51
MACDBearish
VolumeStable
Fear & Greed Index73.48
Valuation
Fair Value$850.95
Target Price$395.10
Upside/Downside42.93%
GradeUndervalued
TypeGrowth
Dividend Yield1.17%
Risk Assessment
Beta1.80
Volatility50.89%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.